BACKGROUND: The etiology of cancers of the small intestine is largely unknown. To gain insight into these rare malignancies, we evaluated contemporaneous incidence and survival patterns. METHODS: Using small intestine cancer data from 12 population-based registries of the Surveillance, Epidemiology and End Results Program, we calculated age-adjusted and age-specific incidence rates (IRs), IR ratios, and relative survival (RS) rates. RESULTS: In total, 10,945 small intestine cancers (IR = 2.10/100,000 person-years) were diagnosed during 1992 to 2006, including carcinomas (n = 3,412; IR = 0.66), neuroendocrine cancers (n = 4,315; IR = 0.83), sarcomas (n = 1,084; IR = 0.20), and lymphomas (n = 2,023, IR = 0.38). For all histologic groups, males had significantly higher IRs than females, and distinct age-specific gender patterns were limited to intermediate-/high-grade lymphomas. Neuroendocrine cancer rates varied significantly by race, with rates highest among blacks and lowest among Asians/Pacific Islanders. Carcinoma IRs were highest among blacks; sarcoma IRs were highest among Asians/Pacific Islanders; and lymphoma IRs were highest among whites. Age-specific IR patterns were similar across racial/ethnic groups. During 1992 to 2006, duodenal cancer IRs increased more markedly than those for other subsites. RS varied little by gender or race. Neuroendocrine cancers had the most favorable RS, and carcinomas had the least favorable. The greatest improvement in 5-year RS from 1992 to 1998 to 1999 to 2005 was observed for sarcomas and lymphomas. CONCLUSIONS: Distinct small intestine cancer IR patterns according to histologic subtype suggest different underlying etiologies and/or disease biology, with susceptibility varying by gender, racial/ethnic groups, and subsite. Temporal patterns support a possible role for diagnostic bias of duodenal cancers. IMPACT: Future epidemiologic studies of small intestine cancer should consider histologic subtype by gender, race/ethnicity, and subsite. (c)2010 AACR.
BACKGROUND: The etiology of cancers of the small intestine is largely unknown. To gain insight into these rare malignancies, we evaluated contemporaneous incidence and survival patterns. METHODS: Using small intestine cancer data from 12 population-based registries of the Surveillance, Epidemiology and End Results Program, we calculated age-adjusted and age-specific incidence rates (IRs), IR ratios, and relative survival (RS) rates. RESULTS: In total, 10,945 small intestine cancers (IR = 2.10/100,000 person-years) were diagnosed during 1992 to 2006, including carcinomas (n = 3,412; IR = 0.66), neuroendocrine cancers (n = 4,315; IR = 0.83), sarcomas (n = 1,084; IR = 0.20), and lymphomas (n = 2,023, IR = 0.38). For all histologic groups, males had significantly higher IRs than females, and distinct age-specific gender patterns were limited to intermediate-/high-grade lymphomas. Neuroendocrine cancer rates varied significantly by race, with rates highest among blacks and lowest among Asians/Pacific Islanders. Carcinoma IRs were highest among blacks; sarcoma IRs were highest among Asians/Pacific Islanders; and lymphoma IRs were highest among whites. Age-specific IR patterns were similar across racial/ethnic groups. During 1992 to 2006, duodenal cancer IRs increased more markedly than those for other subsites. RS varied little by gender or race. Neuroendocrine cancers had the most favorable RS, and carcinomas had the least favorable. The greatest improvement in 5-year RS from 1992 to 1998 to 1999 to 2005 was observed for sarcomas and lymphomas. CONCLUSIONS: Distinct small intestine cancer IR patterns according to histologic subtype suggest different underlying etiologies and/or disease biology, with susceptibility varying by gender, racial/ethnic groups, and subsite. Temporal patterns support a possible role for diagnostic bias of duodenal cancers. IMPACT: Future epidemiologic studies of small intestine cancer should consider histologic subtype by gender, race/ethnicity, and subsite. (c)2010 AACR.
Authors: L G Shack; H E Wood; J Y Kang; D H Brewster; M J Quinn; J D Maxwell; A Majeed Journal: Aliment Pharmacol Ther Date: 2006-05-01 Impact factor: 8.171
Authors: Michael B Cook; Sanford M Dawsey; Neal D Freedman; Peter D Inskip; Sara M Wichner; Sabah M Quraishi; Susan S Devesa; Katherine A McGlynn Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-17 Impact factor: 4.254
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Karl Y Bilimoria; David J Bentrem; Jeffrey D Wayne; Clifford Y Ko; Charles L Bennett; Mark S Talamonti Journal: Ann Surg Date: 2009-01 Impact factor: 12.969
Authors: E Rondonotti; M Pennazio; E Toth; P Menchen; M E Riccioni; G D De Palma; F Scotto; D De Looze; T Pachofsky; I Tacheci; T Havelund; G Couto; A Trifan; A Kofokotsios; R Cannizzaro; E Perez-Quadrado; R de Franchis Journal: Endoscopy Date: 2008-05-08 Impact factor: 10.093
Authors: Bjorn I Gustafsson; Luna Siddique; Anthony Chan; Manku Dong; Ignat Drozdov; Mark Kidd; Irvin M Modlin Journal: Int J Oncol Date: 2008-12 Impact factor: 5.650
Authors: Tao Fu; Emmanouil P Pappou; Angela A Guzzetta; Jana Jeschke; Ruby Kwak; Pujan Dave; Craig M Hooker; Richard Morgan; Stephen B Baylin; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Nita Ahuja Journal: Clin Cancer Res Date: 2012-07-23 Impact factor: 12.531
Authors: L A Anderson; A Tavilla; H Brenner; S Luttmann; C Navarro; A T Gavin; B Holleczek; B T Johnston; M B Cook; F Bannon; M Sant Journal: Eur J Cancer Date: 2015-09-26 Impact factor: 9.162